Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 11% Following Analyst Upgrade
Iovance Biotherapeutics (NASDAQ:IOVA) saw its stock price jump 11% after Mizuho raised its price target from $10 to $11, maintaining an "outperform" rating. The company reported strong Q2 results, exceeding EPS and revenue estimates. While analyst sentiment is mixed with a consensus "Hold" rating, institutional investors have increased their stakes in IOVA.
Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus
Iovance Biotherapeutics (IOVA) is back in focus after reporting strong Q2 2026 results, with revenue of $99.31 million and narrowed losses, alongside a positive full-year revenue guidance. The stock has seen significant recent gains, with a 42% return in 30 days and 184% over one year, fueled by the approval of its first product, Amtagvi. While one valuation model suggests the stock is undervalued with a fair value of $18, another indicates it trades at a premium P/S ratio compared to its own historical average, reflecting investor optimism about its growth prospects and execution ability.
IOVA Maintained by Mizuho -- Price Target Raised to $11.00
Mizuho has maintained an "Outperform" rating on Iovance Biotherapeutics (IOVA) and raised its price target from $10.00 to $11.00, signaling optimism for the company's future in biotechnology. Despite this positive analyst sentiment, IOVA's GF Score™ of 34/100 and high price-to-sales ratio suggest that investors should approach the stock with caution due to low profitability and potential overvaluation.
Rice Hall James & Associates LLC Acquires Shares of 1,539,840 Iovance Biotherapeutics, Inc. $IOVA
Rice Hall James & Associates LLC has acquired 1,539,840 shares of Iovance Biotherapeutics (NASDAQ:IOVA) for approximately $6.4 million, representing about 0.34% of the company. Institutional investors and hedge funds now own 77.03% of IOVA. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $8.00, Iovance recently reported strong quarterly revenues of $198.63 million, significantly exceeding estimates, and a narrower-than-expected loss of $0.11 per share.
Iovance Biotherapeutics Inc : Baird Assumes C
Baird has initiated coverage on Iovance Biotherapeutics Inc. (IOV) with an Outperform rating and a price target of $24.00. This new coverage suggests a positive outlook on the company's future performance.
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA
Bank of America Corp DE significantly reduced its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by selling 5.79 million shares, retaining 8.49 million shares valued at approximately $29.8 million. Despite this reduction, institutional ownership remains high at 77.03%, with other firms like Dimensional Fund Advisors and Vanguard Group Inc. increasing their positions. Analysts have a mixed sentiment with a consensus "Hold" rating and a target price of $8.00, while the company recently beat quarterly EPS estimates and reported strong revenue growth.
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026
Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI readings and price trading above upper Bollinger Bands suggest the rally is stretched. The article advises close attention to the 6.56 to 7.20 range to determine if the next move will be a continuation or consolidation.
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com
Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year. The company's revenue grew by 35% year-over-year to $325 million in Q2 2026. This performance, along with strong Q2 earnings that surpassed Wall Street expectations, highlights investor confidence despite InvestingPro suggesting the stock might be slightly overvalued.
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD
Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, driven by robust sales of its lead cancer therapy, Amtagvi. Despite the current trading price suggesting it might be slightly overvalued according to InvestingPro analysis, its growth potential and recent financial performance have garnered investor interest.
Iovance (IOVA) Q2 2026 Earnings Call Transcript
Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, a 66% year-over-year increase, driven by strong Amtagvi demand and achieving a 56% gross margin. The company is expanding its TIL therapy platform into broader solid tumor indications like non-small cell lung cancer and soft tissue sarcomas, with significant pipeline advancements and international approvals. Iovance anticipates updating its full-year 2026 revenue guidance upwards due to strong commercial momentum and expects to be self-funded into the second half of 2028.
IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast
24/7 Wall St. has issued a "BUY" rating for Iovance Biotherapeutics Inc (IOVA), setting a 12-month target price of $11.41, representing a 71.77% upside from its current price of $6.65. The forecast includes an optimistic scenario of $12.59 and a conservative scenario of $8.46, supported by strong analyst sentiment with 7 out of 9 analysts rating it a Buy. Long-term projections extend to 2030, with an average price target of $21.58.
Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns
Iovance Biotherapeutics (IOVA) stock has seen a significant 221.8% return over the past year, but its current valuation suggests it is now fairly priced rather than cheap. The company scores a mixed 4 out of 6 on Simply Wall St's valuation checks, with a P/S ratio of 8.8x, slightly above its tailored fair P/S of 8.2x. While recent revenue growth from cancer therapies is positive, concerns about execution and funding risks persist among investors.
Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?
Iovance Biotherapeutics (IOVA) is gaining investor attention after reporting improved Q2 2026 results, including higher revenue and a narrower net loss, while reaffirming full-year revenue guidance of US$350-370 million. Despite a recent share price surge and a narrative suggesting it's undervalued at $18 compared to its current $6.34, the company still faces risks like ongoing losses and reliance on a single commercial platform. Its P/S ratio of 8.8x is below industry averages but slightly above a fair ratio, indicating both potential upside and a need for investors to carefully assess the fundamentals.
Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA
Hennion & Walsh Asset Management Inc. significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 100% in the second quarter, now holding 818,913 shares valued at $3.4 million. This move comes as Iovance Biotherapeutics reported strong quarterly revenue growth of 65.7% year-over-year, beating analyst expectations, despite mixed analyst ratings with a consensus "Hold" and an average price target of $8.00. The company specializes in developing tumor-infiltrating lymphocyte (TIL) immunotherapies for solid tumors.
Dimensional Fund Advisors LP Purchases 1,106,592 Shares of Iovance Biotherapeutics, Inc. $IOVA
Dimensional Fund Advisors LP significantly increased its stake in Iovance Biotherapeutics, purchasing over 1.1 million additional shares, bringing its total to 2.65 million shares valued at $9.28 million. This comes as Iovance Biotherapeutics reported strong Q2 2026 results, exceeding revenue and earnings estimates, driven by high demand for its Amtagvi product. Despite positive financial performance and pipeline developments, the company remains unprofitable, with institutional investors holding a substantial 77.03% of its stock.
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
Iovance Biotherapeutics (NASDAQ: IOVA) recently reported strong Q2 earnings, with revenue increasing by 66% due to high demand for its cancer treatment, Amtagvi. The company also significantly reduced its net losses, leading to a surge in stock value and a new 52-week high. Despite past struggles, the approval of Amtagvi makes Iovance a more attractive, albeit still risky, investment with potential for further growth and profitability.
Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Iovance Biotherapeutics, Inc. recently reported its latest quarterly results, surpassing analyst revenue and earnings estimates. This positive performance has led analysts to revise their forecasts upwards, suggesting increased optimism about the company's future earnings potential. The market reacted positively, with the stock price climbing after the announcement.
Form 8K Iovance Biotherapeutics Inc For: 6 August By Investing.com
This article reports on the filing of a Form 8K by Iovance Biotherapeutics Inc. The filing date is stated as August 6th. The article, published by Investing.com, provides no further details beyond the announcement of the 8K filing.
Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside
Iovance Biotherapeutics, Inc. (IOVA) has seen its average 12-month stock price target raised to $8.67 from $8.22 by 9 analysts, implying a potential upside of approximately 100% from its Aug. 5 closing price. The consensus rating for the stock remains "Buy," with 7 analysts recommending Buy and 2 recommending Hold.
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
Iovance Biotherapeutics (IOVA) closed at $6.21, with Wall Street analysts setting a mean price target of $7.95, suggesting a 28% upside. While an impressive consensus price target is noted, the article cautions against relying solely on these targets due to potential analyst optimism and business incentives. However, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for IOVA indicate a legitimate reason to expect an upside in the stock.
State Street Corporation (NYSE: STT) discloses 5.5% Iovance Biotherapeutics stake
State Street Corporation has disclosed a 5.5% beneficial ownership stake in Iovance Biotherapeutics, Inc., as reported in a Schedule 13G SEC filing. This amounts to 24,478,268 shares of Iovance common stock, with shared voting power over 23,483,868 shares and shared dispositive power over all beneficially owned shares. The filing indicates this stake is held through State Street and its investment adviser subsidiaries, including SSGA Funds Management, Inc. and various State Street Global Advisors entities.
IOVANCE BIOTHERAPEUTICS, INC. 2Q 2026: Revenue $99.3M, EPS $(0.11) — 10-Q Summary
IOVANCE BIOTHERAPEUTICS, INC. reported its second-quarter 2026 results, showing significant improvement with revenue of $99.3M and a narrowed net loss of $47.3M. The company's diluted EPS improved to $(0.11), driven by commercial growth, including increased Amtagvi® infusions and higher Proleukin® sales. IOVANCE has also transitioned all TIL manufacturing in-house to its iCTC to scale capacity and reduce costs.
Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30%
Iovance Biotherapeutics (NASDAQ: IOVA) reported stronger-than-expected Q2 2026 results, with adjusted loss per share narrower than anticipated and revenue exceeding forecasts, driven by robust sales of its cancer therapy Amtagvi. Shares jumped over 30% in premarket trading. The company also announced improved gross margins, a solid cash position, and plans to update its full-year guidance as demand for its products continues to grow.
Iovance stock surges as Amtagvi powers Q2 beat (IOVA:NASDAQ)
Iovance Biotherapeutics (IOVA) stock surged over 40% to a new 52-week high after reporting Q2 2026 earnings that significantly exceeded Wall Street expectations. The strong performance was attributed to its cancer therapy, Amtagvi. The company maintained its revenue outlook under review.
Iovance Biotherapeutics Stock Grants Signal Post-Amtagvi Expansion
Iovance Biotherapeutics (NASDAQ: IOVA) is experiencing a 31.57% stock increase driven by positive sentiment surrounding its Amtagvi trial progress and a new hiring wave. The company granted inducement stock options for 139,930 shares to 17 new non-executive hires, indicating a significant expansion post-FDA approval of its TIL therapy, Amtagvi. This move suggests management's confidence in future demand and commercial build-out, attracting traders despite the company's current losses as it transitions from development to commercialization.
Iovance Biotherapeutics stock hits 52-week high at $5.97 By Investing.com
Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $5.97, reflecting a 64.39% appreciation over the past year. The company, which specializes in cancer immunotherapies, currently trades at $6.21 with a market capitalization of $1.94 billion. This milestone follows better-than-expected Q2 2026 results, with revenue of $99.31 million and a narrower adjusted loss per share, driven by strong sales of its cancer therapy, Amtagvi.
IOVA Stock Grants Signal Aggressive Post-Amtagvi Expansion
Iovance Biotherapeutics Inc. (IOVA) has granted inducement stock options for 139,930 shares to 17 new non-executive hires, signaling an aggressive post-Amtagvi expansion. These grants, with a $4.66 strike price and a three-year vesting period, suggest management's confidence in long-term growth following the FDA approval of its TIL cancer therapy. While the company faces high R&D costs and quarterly losses, it maintains a strong cash position, providing runway for commercialization efforts.
Earnings Flash (IOVA) Iovance Biotherapeutics, Inc. Reports Q2 Revenue $99.3M, vs. FactSet Est of $87.8M
Iovance Biotherapeutics, Inc. (IOVA) announced strong Q2 revenue, reaching $99.3 million, significantly surpassing FactSet's estimated $87.8 million. This positive financial performance was released alongside other company updates, including recent regulatory approvals for its Amtagvi therapy in Australia and FDA clearance for a new clinical trial. The company specializes in developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients.
Iovance Biotherapeutics reports record Q2 revenue ~$99.3M, gross margin 56%
Iovance Biotherapeutics reported record second-quarter 2026 product revenue of $99.3 million with a 56% gross margin, driven by strong U.S. Amtagvi demand. The company is reviewing its full-year 2026 revenue guidance following these robust results and expects continued gross margin improvement. Key highlights include expanding the Authorized Treatment Center (ATC) network, efficient manufacturing, regulatory progress, and international expansion efforts for Amtagvi and other pipeline candidates.
Iovance Biotherapeutics Reports Record Second Quarter 2026
Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, a 66% increase year-over-year, driven by strong U.S. Amtagvi demand. The company is reviewing its full-year 2026 revenue guidance of $350 million to $370 million and expects to provide an update in the third quarter. Key achievements include the expansion of Amtagvi's commercial business, FDA Fast Track Designation for lifileucel in soft tissue sarcomas, and progress across its clinical and regulatory pipeline.
Iovance Biotherapeutics: Q2 Earnings Snapshot
Iovance Biotherapeutics (IOVA) reported a Q2 loss of $47.3 million, or 11 cents per share, with revenue reaching $99.3 million. The biotechnology company anticipates full-year revenue to be between $350 million and $370 million. This financial update was generated using data from Zacks Investment Research.
Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – FWB:2LB
This article displays the Enterprise Value to EBIT forward for Iovance Biotherapeutics Inc (FWB:2LB) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades. The content is presented as a financial overview for the company.
Iovance Biotherapeutics (IOVA) Stock May Be Cheap As Sales Ramp Remains Key
Iovance Biotherapeutics (IOVA) stock is showing signs of being undervalued according to Simply Wall St's framework, despite a significant 5-year decline. The valuation hinges on the company's ability to generate reliable revenue from its therapies and control cash burn. While it scores well on valuation measures like P/S ratio compared to industry averages, the market remains divided between optimism for commercialization and concerns over funding and execution risks.
Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus
Iovance Biotherapeutics (IOVA) is approaching its Q2 2026 earnings report on August 6, 2026, with investors focusing on its first FDA-approved T cell therapy for solid tumors. Despite recent share price pullbacks, the company shows strong short-term momentum and is considered significantly undervalued by analysts, with a fair value target of $18.00 against its current trading price of $4.07. The narrative highlights the potential for substantial growth if Amtagvi's uptake meets expectations, though risks related to trial results and commercial execution remain.
Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc
A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) on behalf of investors who suffered losses due to alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth potential, and its stock price significantly declined after the company reduced its 2024 revenue guidance. Shareholders are encouraged to contact Levi & Korsinsky to learn about their rights to recover losses before July 14, 2025.
Iovance Biotherapeutics (IOVA) Stock Looks Cheap On Sales While Returns Stay Weak
Iovance Biotherapeutics (IOVA) stock appears undervalued based on its sales multiple, trading at 6.4x sales compared to the biotech industry average of 10.5x and a tailored fair P/S ratio of 7.1x. Despite a recent rebound, long-term investors still face significant losses over five years, highlighting the company-specific risks. The key challenge for Iovance is converting its pipeline, including the recently approved Amtagvi, into sustainable revenue while managing funding and execution risks.
IOVA Stock Slides As Biotech Traders Watch Key Support
Iovance Biotherapeutics Inc. (IOVA) stock has dropped significantly, trading down 14.07% due to concerns over its cancer therapy pipeline. While the company has substantial cash reserves and modest debt, it remains unprofitable with high R&D spending. Traders are closely monitoring the $4 support level, anticipating either a further breakdown or a bounce-back, emphasizing reactive trading strategies over predictions.
Iovance Sets Aug. 6 Webcast to Discuss Second-Quarter Results
Iovance Biotherapeutics (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to report its second quarter 2026 financial results and provide corporate updates. Investors can access the live or archived webcast through the provided Media Server link or the Investors section of IR.Iovance.com. The archived webcast will be available for one year, and the company's previous earnings-date announcements have shown an average negative 24-hour price reaction.
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
Iovance Biotherapeutics, Inc. announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide corporate updates. The company, focused on developing TIL therapies for cancer, will make the webcast accessible through its investors section for one year.
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide corporate updates. The company is a biotechnology firm focused on developing cancer therapies using tumor infiltrating lymphocyte (TIL) cells, and its product Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. The webcast will be accessible through the company's investor relations website and will be archived for one year.
Iovance Biotherapeutics Inc (IOVA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Iovance Biotherapeutics Inc (IOVA), noting its current score of 4.11 and its ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.74, indicating less volatility than the S&P 500, and presents various metrics for volatility, maximum drawdown, return-to-drawdown ratio, skewness, and liquidity. The assessment helps investors understand IOVA's risk profile based on these financial indicators.
Iovance Biotherapeutics to Report Second Quarter 2026
Iovance Biotherapeutics, Inc. announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second-quarter 2026 financial results and provide corporate updates. The company, focused on developing TIL therapies for cancer, will make the webcast available on its Investors section for one year.
Iovance Biotherapeutics Inc (IOVA) Institutional Confidence
Iovance Biotherapeutics Inc (IOVA) has an institutional shareholding score of 5.00, placing it 132nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 69.13%, marking an 11.55% increase quarter-over-quarter. MHR Fund Management LLC is listed as the largest institutional shareholder with 28.97 million shares.
BlackRock (IOVA holder) reports 33.4M Iovance Biotherapeutics shares, a 7.5% stake
BlackRock, Inc. has reported a 7.5% stake in IOVANCE BIOTHERAPEUTICS, INC. (IOVA), beneficially owning 33,366,587 shares as of June 30, 2026. The firm holds sole voting power over 32,842,318 shares and sole dispositive power over all 33,366,587 shares, with no single underlying client holding more than five percent of Iovance's total outstanding common shares. This information was disclosed in an amended SCHEDULE 13G/A filing.
IOVA|Iovance Biotherapeutics Inc|Price:4.900|Chg%:-0.090
Iovance Biotherapeutics Inc (IOVA) shows healthy fundamentals, high growth potential with revenue growth averaging 22061.65% year-on-year, and is considered fairly valued. Institutional ownership is high, and analysts rate it as a Buy with a target price of $8.80, suggesting a potential upside of 76.35%. Despite strong performance and fundamentals, technical indicators suggest the stock is trading sideways, suitable for range-bound swing trading.
Iovance Biotherapeutics Inc Revenue Breakdown – BX:IOVA
Iovance Biotherapeutics Inc. (BX:IOVA) reported total revenue of 208.90 million CHF last year. The primary revenue driver was its Autologous Tumor Infiltrating Lymphocyte Cell Therapies segment, which generated the same amount. The majority of this revenue, 205.34 million CHF, originated from the United States.
IOVA|Iovance Biotherapeutics Inc|Price:4.990|Chg%:-0.140
Iovance Biotherapeutics Inc. is a commercial biotechnology company focused on developing and delivering novel tumor-infiltrating lymphocyte (TIL) therapies for cancer patients. Their key product, Amtagvi, is an autologous T cell immunotherapy for unresectable or metastatic melanoma, used in conjunction with Proleukin. The company is actively developing its pipeline to include TIL cell therapies for various solid tumor cancers and genetically modified TIL cell therapies.
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Iovance Biotherapeutics Inc (IOVA), noting that some detailed business segment data has not yet been disclosed by the company. It highlights that the vast majority of the company's revenue, $259.01 million (98.30%), is generated in the United States, with only a small portion from the rest of the world. The company's stock price, market cap, and relevant financial periods are also listed.
Iovance Biotherapeutics Inc (IOVA) Income Statement: Quarterly and Annual Data
This article provides detailed quarterly and annual income statement data for Iovance Biotherapeutics Inc (IOVA), including metrics such as total revenue, cost of revenue, operating expenses, R&D expenses, operating profit, and net income. It also includes frequently asked questions about how to interpret the income statement and key financial figures for the company. The financial data reveals fluctuating revenue and persistent net losses for the company over several fiscal periods.
Iovance Biotherapeutics Inc Revenue Breakdown – MIL:1IOVA
Iovance Biotherapeutics Inc (MIL:1IOVA) generated 224.35 million EUR in revenue last year, with its Autologous Tumor Infiltrating Lymphocyte Cell Therapies segment being the primary contributor. The United States was the leading geographical source of revenue for the company. This marks an increase from the 158.49 million EUR recorded in the previous year.
